Myeloma (Multiple Myeloma) – A Comprehensive Medical Guide

Overview

Multiple myeloma is a cancer of plasma cells, a type of white blood cell that produces antibodies (immunoglobulins) to fight infection. In myeloma, abnormal plasma cells multiply uncontrollably, crowding out normal blood‑forming cells in the bone marrow and producing large amounts of a single, defective antibody called monoclonal protein (M‑protein).

• Who it affects: It is primarily a disease of older adults. The median age at diagnosis is 69 years, and about 60 % of patients are men.¹
• Prevalence: In the United States, an estimated 34,920 new cases are diagnosed each year, and approximately 176,000 people are living with the disease (2023 data).²
• Geography: Incidence is slightly higher in North America and Western Europe, and lower in Asia and Africa, suggesting a role for genetics and environmental factors.

Symptoms

Myeloma often develops slowly, and many patients are asymptomatic at the time of blood testing for another problem. When symptoms appear, they can be grouped into several categories.

Bone‑related symptoms

• Bone pain: Usually in the back, ribs, hips, or skull; pain may be dull and persistent.
• Pathologic fractures: Bones become weak and can break with minimal trauma.
• Hypercalcemia: Elevated blood calcium caused by bone breakdown leads to nausea, constipation, confusion, and increased thirst.

Blood‑related symptoms

• Anemia: Fatigue, pallor, shortness of breath due to reduced red blood cells.
• Thrombocytopenia: Easy bruising or bleeding because of low platelet counts.
• Renal impairment: Dark urine, swelling of the ankles, or decreased urine output.

Immune system symptoms

• Recurrent infections: Especially bacterial infections of the lungs, skin, or urinary tract.
• Peripheral neuropathy: Tingling, numbness, or burning sensations, often from medication (e.g., bortezomib) rather than the disease itself.

Systemic “CRAB” features

Clinicians summarize the classic presenting signs with the acronym CRAB:

• C – Calcium elevation (hypercalcemia)
• R – Renal insufficiency
• A – Anemia
• B – Bone lesions or fractures

Other possible symptoms

• Weight loss and loss of appetite
• Generalized weakness
• Night sweats
• Unexplained fevers

Causes and Risk Factors

Exactly why a plasma cell becomes malignant is not fully understood, but several factors increase risk.

Genetic and biological factors

• Cytogenetic abnormalities: Translocations involving the immunoglobulin heavy‑chain locus (e.g., t(4;14), t(14;16)) and deletions of chromosome 17p are associated with higher risk and poorer prognosis.³
• Family history: First‑degree relatives of myeloma patients have a two‑ to three‑fold increased risk.
• Monoclonal gammopathy of undetermined significance (MG ≥ S): A benign precursor condition present in ~3 % of people >50 years; ~1 % per year progress to multiple myeloma.

Environmental and lifestyle factors

• Exposure to ionizing radiation (e.g., atomic bomb survivors).⁴
• Occupational exposure to certain chemicals (benzene, pesticides, petroleum products).⁵
• Obesity: Body‑mass index (BMI) ≥ 30 is linked to a 20‑30 % higher incidence.

Demographic factors

• Age: Risk rises sharply after age 50.
• Sex: Men are about 1.5 times more likely than women.
• Race/Ethnicity: African‑American individuals have a 2‑3 fold higher incidence and are diagnosed at a younger age compared with Caucasians.⁶

Diagnosis

Diagnosing myeloma requires a combination of laboratory tests, imaging studies, and bone‑marrow evaluation.

Laboratory tests

• Complete blood count (CBC): Detects anemia, leukopenia, or thrombocytopenia.
• Serum calcium and creatinine: Screens for hypercalcemia and renal dysfunction.
• Serum protein electrophoresis (SPEP) and immunofixation: Identify the M‑protein and its type (IgG, IgA, light chain, etc.).
• Serum free light‑chain assay: Sensitive for light‑chain disease and for monitoring response.
• Beta‑2‑microglobulin and lactate dehydrogenase (LDH): Provide prognostic information.

Bone‑marrow examination

A trephine biopsy from the posterior iliac crest is performed to:

• Demonstrate ≥10 % clonal plasma cells (or <10 % with CRAB features).⁷
• Allow cytogenetic and molecular testing (FISH, next‑generation sequencing).

Imaging studies

• Low‑dose whole‑body CT or MRI: Detects osteolytic lesions, fractures, and soft‑tissue masses.
• PET‑CT: Helpful for assessing disease activity and extramedullary involvement.
• Conventional skeletal survey: Historically used; less sensitive than CT/MRI.

Staging systems

Two widely accepted systems are used:

• International Staging System (ISS): Based on serum beta‑2‑microglobulin and albumin.
• Revised ISS (R‑ISS): Adds cytogenetics and LDH for finer prognostication.

Treatment Options

Treatment is individualized based on disease stage, patient fitness, and cytogenetic risk. Goals are to achieve deep remission, prolong survival, and maintain quality of life.

Front‑line (induction) therapy

For transplant‑eligible patients (usually ≤ 70 years and fit), a typical regimen includes a proteasome inhibitor, an immunomodulatory drug (IMiD), and dexamethasone (often abbreviated VRd – bortezomib, lenalidomide, dexamethasone).

• Proteasome inhibitors: Bortezomib, carfilzomib, ixazomib.
• IMiDs: Lenalidomide, thalidomide, pomalidomide.
• Monoclonal antibodies: Daratumumab (anti‑CD38) and elotuzumab (anti‑SLAMF7) have become backbone agents.

Autologous stem‑cell transplantation (ASCT)

High‑dose melphalan followed by infusion of the patient’s own previously collected stem cells. ASCT improves progression‑free survival (PFS) and is standard for eligible patients.

Consolidation and maintenance

• Maintenance therapy: Lenalidomide (or ixazomib) is given for 2‑3 years or until disease progression, extending PFS by 2‑3 years in many trials.⁸
• Consolidation cycles: Additional short courses of the induction regimen post‑ASCT to deepen response.

Relapsed/refractory disease

When the disease returns, options depend on prior exposure:

• Second‑generation proteasome inhibitors (carfilzomib, ixazomib)
• IMiD switch (e.g., pomalidomide after lenalidomide)
• Antibody‑drug conjugates (belantamab mafodotin)
• CAR‑T cell therapy targeting BCMA (e.g., idecabtagene vicleucel) – FDA‑approved for heavily pre‑treated patients.
• Bispecific T‑cell engagers (e.g., teclistamab) – emerging options.

Supportive care

• Bisphosphonates or denosumab: Prevent skeletal events.
• Vaccinations: Influenza, pneumococcal, COVID‑19, and shingles (if immunocompetent).
• Antibiotic prophylaxis: Trimethoprim‑sulfamethoxazole for Pneumocystis jirovecii; antivirals for herpes‑virus reactivation when using proteasome inhibitors.
• Growth factors: G‑CSF for neutropenia, erythropoietin for symptomatic anemia.

Living with Myeloma (Multiple Myeloma)

Daily management tips

• Medication adherence: Use pillboxes, set alarms, and keep a medication list.
• Hydration: Aim for 2–3 L of fluid daily (unless restricted for heart/kidney disease) to reduce kidney injury.
• Nutrition: Balanced diet rich in protein, calcium (if not hypercalcemic), vitamin D, and fiber; limit processed meats and excess alcohol.
• Exercise: Low‑impact activities (walking, yoga, resistance bands) improve bone health, fatigue, and mood. Consult a physiotherapist familiar with cancer patients.
• Bone safety: Use assistive devices (grab bars, cane) to prevent falls; avoid heavy lifting.
• Regular monitoring: Labs every 1–3 months (CBC, calcium, creatinine, M‑protein) and imaging as recommended by the oncologist.
• Psychosocial support: Join myeloma support groups, seek counseling, and consider mindfulness or CBT for anxiety/depression.
• Vaccination schedule: Stay up‑to‑date; avoid live vaccines if severely immunocompromised.

Financial and practical resources

• Patient assistance programs from drug manufacturers
• Non‑profit organizations: International Myeloma Foundation (IMF), Multiple Myeloma Research Foundation (MMRF)
• Insurance navigation services for high‑cost therapies (CAR‑T, monoclonal antibodies)

Prevention

Because myeloma originates from genetic mutations that cannot be fully prevented, the focus is on risk reduction:

• Maintain a healthy weight and engage in regular exercise.
• Limit exposure to known carcinogens (avoid benzene, stop smoking, use protective equipment if working with chemicals).
• Manage chronic conditions (e.g., control diabetes, hypertension) that may indirectly affect bone health.
• Discuss occupational hazards with employers and follow safety guidelines.
• For individuals with MGUS, follow a surveillance plan—early detection of progression can improve outcomes.

Complications

If left untreated or inadequately controlled, myeloma can lead to serious, potentially life‑threatening complications.

• Pathologic fractures and spinal cord compression: May cause permanent neurologic deficits.
• Renal failure: Light‑chain cast nephropathy can become irreversible.
• Hyperviscosity syndrome: Thickened blood leading to visual changes, headaches, or bleeding.
• Severe infections: Due to immune suppression and hypogammaglobulinemia.
• Secondary primary cancers: Particularly acute myeloid leukemia (AML) after prolonged alkylating agent exposure.
• Cardiovascular disease: Increased risk from certain therapies (e.g., carfilzomib) and from chronic anemia.
• Peripheral neuropathy: Chronic pain and loss of sensation, often from bortezomib or thalidomide.

When to Seek Emergency Care

---

Sources: 1. Mayo Clinic. Multiple Myeloma. 2023. 2. American Cancer Society. Cancer Facts & Figures 2024. 3. International Myeloma Working Group. Cytogenetics. Blood, 2022. 4. CDC. Radiation and Cancer. 5. NIH. Occupational Carcinogens. 6. Kyle RA et al. Racial differences in Multiple Myeloma. Lancet Oncology, 2021. 7. NCCN Guidelines Version 2.2024. 8. Palumbo A et al. Lenalidomide maintenance after ASCT. NEJM, 2020.